TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01024140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
Study: NCT03731481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle Medicine programs provide instruction in plant-based nutrition, food preparation, methods of stress reduction and incorporation of physical activity into daily routine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle Medicine programs provide instruction in plant-based nutrition, food preparation, methods of stress reduction and incorporation of physical activity into daily routine.
Study: NCT00492648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling for assay of persistence of immunogenicity
Description: Two blood samples: 30 and 42 months after first vaccination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling for assay of persistence of immunogenicity
Description: Two blood samples: 30 and 42 months after first vaccination
Study: NCT02078245

Intervention type: OTHER
Intervention: MRI
Description: MRI
Study: NCT02012361

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target FiO2 of 0.25, (25%oxygen / 75%nitrogen) the only exception being that they will not be treated with inspired heliox.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Dose Heliox Group
Description: This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes over any convenient window prior to the inflation of the surgical tourniquet. This will be the only change in their clinical care. Their anesthesia will be conducted as per routine and as the anesthesia team sees fit with a target FiO2 of 0.25, the only exception being that they will receive 75/25 heliox prior to the inflation of the tourniquet.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Biopsy
Description: During the course of the operation a small muscle biopsy will be collected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Biopsy
Description: During the course of the operation a small muscle biopsy will be collected.
Study: NCT04452214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN04
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN04
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously
Study: NCT02035449

Intervention type: DEVICE
Intervention: McGrath MAC
Description: McGrath MAC is a videolaryngoscope
Study: NCT00409487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: 8 weeks of CPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: 8 weeks of CPAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartant treatment
Description: 8 weeks of Valsartant treatment (160 mg / day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartant treatment
Description: 8 weeks of Valsartant treatment (160 mg / day)
Study: NCT03426124

Intervention type: DEVICE
Intervention: EkoSonic Endovascular System with thrombolytic
Description: The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.

Intervention type: DEVICE
Intervention: EkoSonic Endovascular System with thrombolytic
Description: The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.
Study: NCT02730403

Intervention type: OTHER
Intervention: Treatment As Usual
Study: NCT01209000

Intervention type: PROCEDURE
Intervention: Kidney Biopsy
Description: Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

Intervention type: PROCEDURE
Intervention: Kidney Biopsy
Description: Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

Intervention type: PROCEDURE
Intervention: Kidney Biopsy
Description: Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.
Study: NCT04160039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle ergometry
Description: Lower extremity cycle ergometry, passive and/or active, up to 20 minutes per session, up to 5 sessions per week
Study: NCT01175096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD001 (everolimus, Afinitor®)
Description: RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home.~2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days.
Study: NCT00386672

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reduced energy (lite) OJ fortified with Calcium and Vitamin D
Description: Three 240ml servings of lite OJ fortified with 350mg Ca and 100U VitD per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Individual and group nutritional counseling by a registered dietician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Counseling
Description: Individual and group nutritional counseling by a registered dietician.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reduced energy (lite) OJ without Calcium and Vitamin D
Description: Three 240ml servings of lite OJ without 350mg Ca and 100U VitD per day.
Study: NCT01094444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin K3
Description: Lotion containing 1.5 mM Vitamin K3
Study: NCT03591549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faslodex
Description: intramuscular injection monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: intramuscular injection monthly
Study: NCT04634409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etesevimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etesevimab
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-7831
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bebtelovimab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bebtelovimab
Description: Administered IV.
Study: NCT04625582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face
Description: The intervention has been created specifically for this group of trainees, with the aim of acquiring or improving mediating personal skills in the processes of physical and mental well-being that help them cope with more motivation, enthusiasm and personal resources professional challenges.~It is based on conducting 4-hour face-to-face workshops, every four months throughout the period of specialized health training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing.~Audiovisual media (videos, presentations, recordings) will be used. They will be developed in person in a classroom equipped with the necessary means for training, including versatility of the space.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online
Description: The online intervention will pursue the same objectives and will be nourished by the same content as the face-to-face intervention. The theoretical content will be adapted for online use, with the flexibility of access and organization that this entails for the participants, including videos, presentations, recordings ...~Group techniques will be carried out online, every four months during the entire period of specialized health professional training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing.
Study: NCT02078063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: 10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
Study: NCT03831633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akynzeo
Description: 1 single oral dose of NEPA (capsule) on Day 1 to be administered approximately 1 hour prior chemotherapy (containing 300 mg netupitant and 0.5 mg palonosetron).~- Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: * oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~* IV ondansetron 8 mg on Day 1~* Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4
Study: NCT02935075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Oral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: Oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Oral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Oral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Oral daily
Study: NCT03753854

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: polysomnography and oxygen saturation exam
Description: Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: polysomnography and oxygen saturation exam
Description: Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment
Description: calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment
Description: calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiological measurements
Description: Evaluation of microvascular reactivity and autonomic nervous system activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological measurements
Description: Evaluation of microvascular reactivity and autonomic nervous system activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure during 1 year
Study: NCT00991770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Two 20 minute chair massages: one before surgery and one after

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
Study: NCT01694511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HRME+CVC
Description: High resolution magnification endoscopy with computed virtual chromoendoscopy and directed biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional endoscopy
Description: Conventional white light endoscopy with four-quadrant biopsy
Study: NCT02862639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: patient receive intra articular injection (hip joint) of corticosteroid alone
Study: NCT03905291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT921
Description: Formulated as an injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT921
Description: Formulated as an injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT921
Description: Formulated as an injectable solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study: NCT01274728

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention with at least use of drug-eluting balloon and if necessary cross-over to bail-out stenting with BMS.
Study: NCT02030574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and fractionated cisplatin (combination treatment)
Description: 1 Cycle = 21 days. GC x 4 cycles ----\> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
Study: NCT02990832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exciton
Description: Exsalt® Wound Dressings will be applied by the physician/nursing staff.~The test product, exsalt® Wound Dressings (0.4 mg Ag/cm2) will be applied after wound cleansing or debridement if required.~Dressings will be changed weekly, either at the out-patient facility or at home with provided dressings. At regular intervals throughout the study, as per the existing Diabetes Foot Care Clinical Care Pathway, wound assessment including size determination, Exsalt Wound Assessment Form, any adverse events will be reported, with tracing and/or photography included where available.~Maximum treatment course will be 28 days (end of study) or until wound closure.
Study: NCT04867161

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers sampling
Description: Laboratory sampling:~Haematology: complete blood count, reticulocytes, IFP, PT, aPTT, fibrinogen, D-dimer Biochemical profile: urea, creatinine, bilirubin, ALT, AST, GGT, CK, LD, ferritin, troponin Inflammation markers IL-6, PCT (procalcitonin), CRP (C-reactive protein), PSP (presepsin)~BALF (bronchoalveolar lavage fluid) processing protocol:~1. microbiology: microscopic examination, standard cultivation test~2. biochemistry: albumin, total protein~3. Pathology: cytology~4. PCR:~a. Multiplex PCR b. SARS-CoV-2 RNA load

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers sampling
Description: Laboratory sampling:~Haematology: complete blood count, reticulocytes, IFP, PT, aPTT, fibrinogen, D-dimer Biochemical profile: urea, creatinine, bilirubin, ALT, AST, GGT, CK, LD, ferritin, troponin Inflammation markers IL-6, PCT (procalcitonin), CRP (C-reactive protein), PSP (presepsin)~BALF (bronchoalveolar lavage fluid) processing protocol:~1. microbiology: microscopic examination, standard cultivation test~2. biochemistry: albumin, total protein~3. Pathology: cytology~4. PCR:~a. Multiplex PCR b. SARS-CoV-2 RNA load
Study: NCT00845585

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Below Knee Arterial Reconstruction
Description: Patency, Reinterventions, Amputations, mortality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Below Knee Arterial Reconstruction
Description: Patency, Reinterventions, Amputations, mortality
Study: NCT00851032

Intervention type: OTHER
Intervention: Molecular Profiling Analyses
Description: Molecular profiling analyses from advanced cancer participants' stored tissue bank samples.
Study: NCT00403286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Formoterol Fumarate
Description: Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Formoterol Fumarate
Description: Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Formoterol Fumarate
Description: Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Formoterol Fumarate
Description: Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate
Description: Inhalation Solution for nebulization 20 mcg bid for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate/Salmeterol Xinafoate
Description: Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation Solution for nebulization 2 mL bid for 2 weeks
Study: NCT01396941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Sleep restriction will consist of 5 nights, sleeping 4 hours per night Normal sleep will consist of 5 nights, sleeping 9 hours per night
Study: NCT04499183

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructo- and galacto-oligosaccharides
Description: 15 gram/day fructo- and galacto-oligosaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fructo- and galacto-oligosaccharides
Description: 15 gram/day fructo- and galacto-oligosaccharides
Study: NCT04873674

Intervention type: OTHER
Intervention: ASD diagnosis
Description: Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
Study: NCT03074383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
Study: NCT03835403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activation of HeartRunners
Description: Activation of volunteer citizen first-responders to respond to nearby cardiac arrests
Study: NCT02963922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Description: Injected subcutaneously (s.c., under the skin) once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (s.c., under the skin) once daily
Study: NCT04047680

Intervention type: DRUG
Intervention: Sofosbuvir / Velpatasvir Oral Tablet
Description: Sofosbuvir/velpatasvir for 12 weeks

Intervention type: DRUG
Intervention: Sofosbuvir and Ledipasvir
Description: Sofosbuvir and ledipasvir for 12 weeks

Intervention type: DRUG
Intervention: Sofosbuvir Tablets
Description: Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks

Intervention type: DRUG
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Ombitasvir/paritaprevir/ritonavir for 12 weeks

Intervention type: DRUG
Intervention: Elbasvir / Grazoprevir Oral Tablet
Description: Elbasvir/grazoprevir for 12 weeks

Intervention type: DRUG
Intervention: Glecaprevir and Pibrentasvir
Description: Glecaprevir/pibrentasvir for 12 weeks